Treatment of glioblastoma with current oHSV variants reveals differences in efficacy and immune cell recruitment
Open Access
- 29 July 2021
- journal article
- research article
- Published by Elsevier in Molecular Therapy-Oncolytics
- Vol. 22, 444-453
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (P01 CA163205, R01 CA222804-03, T32 CA082084-19)
This publication has 38 references indexed in Scilit:
- Improved survival time trends for glioblastoma using the SEER 17 population-based registriesJournal of Neuro-Oncology, 2011
- Nestin in gastrointestinal and other cancers: Effects on cells and tumor angiogenesisWorld Journal of Gastroenterology, 2011
- A Double Mutation in Glycoprotein gB Compensates for Ineffective gD-Dependent Initiation of Herpes Simplex Virus Type 1 InfectionJournal of Virology, 2010
- Gr-1+ cells, but not neutrophils, limit virus replication and lesion development following flank infection of mice with herpes simplex virus type-1Virology, 2010
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cellsBMC Medicine, 2008
- An Oncolytic HSV-1 Mutant Expressing ICP34.5 under Control of a Nestin Promoter Increases Survival of Animals even when Symptomatic from a Brain TumorCancer Research, 2005
- Parenchymal Microglia of Naı̈ve Adult C57BL/6J Mice Express High Levels of B7.1, B7.2, and MHC Class IIExperimental and Molecular Pathology, 2002
- Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trialGene Therapy, 2000
- Mapping of Herpes Simplex Virus-1 Neurovirulence to γ 1 34.5, a Gene Nonessential for Growth in CultureScience, 1990